/
CUE
$30.43+$5.04 (+19.85%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$106.6M
4M shares
52-week range
$4.97 – $41.42
70% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
36.58%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-337.37
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $3.5M | $3.2M | $14.9M | $1.2M | $5.5M | $9.3M | $27.5M |
| Cost of revenue | $28.5M | $27.5M | $33.5M | −$1.8M | $0 | $38.1M | $0 | $0 |
| Gross profit | −$27.4M | −$24.0M | −$30.4M | $16.7M | $1.2M | −$32.6M | $9.3M | $27.5M |
| Gross margin | -2398.2% | -694.8% | -963.5% | 111.9% | 100.0% | -593.9% | 100.0% | 100.0% |
| R&D | $28.5M | $27.5M | $33.5M | $41.3M | $38.6M | $40.8M | $36.3M | $37.7M |
| Operating income | −$38.7M | −$36.8M | −$45.0M | −$43.7M | −$53.2M | −$52.1M | −$41.5M | −$26.5M |
| EBITDA | −$37.9M | −$36.0M | −$44.0M | −$45.4M | −$50.5M | −$46.1M | −$37.5M | −$22.3M |
| Net income | −$39.0M | −$36.7M | −$44.8M | −$44.2M | −$53.0M | −$50.7M | −$40.7M | −$26.6M |
| Net margin | -3411.5% | -1061.2% | -1419.8% | -295.6% | -4257.8% | -924.1% | -438.0% | -96.9% |
| EPS (diluted) | -58.20 | -49.80 | -46.80 | -42.30 | -44.70 | -33.30 | -21.60 | -8.40 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-6.64 | $-6.64–$-6.64 | 1 |
| 2027 | $1M | $-9.45 | $-9.45–$-9.45 | 1 |
| 2028 | $1M | $-15.30 | $-15.30–$-15.30 | 1 |
| 2029 | $1M | $-15.60 | $-15.60–$-15.60 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Cue Biopharma, Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
www.cuebiopharma.com- Employees
- 29
- IPO / List date
- Jan 2, 2018
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds CUE.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CUE as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-04-24 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded CUE yet.
